Metastatic teratoma from a regressed impalpable testicular primary

Paul D. Abel and Gordon Williams

Department of Surgery, Hammersmith Hospital and Royal Postgraduate Medical School, Du Cane Road, London W12 0HS, UK.

Summary: A young man presented with a perineal tumour which despite intensive investigation, remained of unknown origin and required radical excision. It was subsequently shown to be a metastasis from a primary regressed testicular teratoma. It is important to exclude a testicular origin in these patients wherever possible because such tumours are often chemosensitive.

Introduction

The majority of germ cell tumours in the male present as a scrotal swelling but a significant minority present in an unorthodox fashion. With the present ability to cure over 70% of patients with metastatic germ cell tumours, a knowledge of the unusual manifestations is of practical importance.

Case report

A man of 29 presented with a 9-month history of haematuria and slow urinary stream. There was no history of testicular maldescent. He did not have gynaecomastia and both testicles were normal but pelvic examination revealed a tender perineal mass. Urethroscopic biopsy showed an infiltrating poorly differentiated carcinoma of uncertain origin. There was no clinical, radiological or biochemical evidence of tumour in other sites. Testicular tumour markers alpha-feto protein (AFP), beta human chorionic gonadotrophin (HCG) and alkaline phosphatase (ALP) were normal. He underwent total emasculinization and formation of an ileal conduit because of the position of the mass.

Histology of the resected tumour revealed malignant teratoma undifferentiated. In addition, a dense fibrous scar was present in the upper pole of the left testis. The perineal mass clearly represented a metastatic deposit from a regressed primary malignant teratoma originally sited in the upper pole of the left testis. This testis also showed extensive in situ seminoma.

Following discharge he developed pulmonary metastases but these resolved after a course of chemotherapy. He remains well with no further evidence of recurrence three years after treatment.

Discussion

The significance of testicular scars as sites of primary gonadal tumours in patients presenting with metastatic testicular teratomas is well recognized. Most of the secondary tumours are chorio-carcinomas but all forms of malignant teratoma have been described. Similarly the presence of seminoma or in situ seminoma adjacent to the scar have also been reported. These lesions are impalpable and, when not associated with an elevated tumour marker, cannot be diagnosed unless testicular biopsies are performed. Even then some cases will be missed. Gynaecomastia is often associated with these tumours but was not present in our patient. In a series of 16 patients with extra-gonadal germ cell tumours, the authors suggested that germ cell malignancy should be considered in any young men with metastatic disease of unknown primary origin and that serum levels of AFP, beta HCG and ALP should be estimated. Further, the testis should be carefully examined in a man presenting with large lymph nodes and an abdominal mass or mediastinal shadows. It is also reported that there is an association between occult primary malignancy and testicular atrophy and/or testicular pain. All these tests were performed in our patient, but did not contribute to his diagnosis or management.

Every effort should be made to exclude a testicular neoplasm in a male presenting with an unknown primary. These tumours are sensitive to chemotherapy and radical surgery may be unnecessary.

Correspondence: P.D. Abel, M.B., F.R.C.S.
Accepted: 12 August 1986

© The Fellowship of Postgraduate Medicine, 1987
References

Metastatic teratoma from a regressed impalpable testicular primary.

P. D. Abel and G. Williams

Postgrad Med J 1987 63: 143-144
doi: 10.1136/pgmj.63.736.143

Updated information and services can be found at:

http://pmj.bmj.com/content/63/736/143

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/